Official ESCRS | European Society of Cataract & Refractive Surgeons


Clinical effectiveness and safety of phaco combined with iStent inject G1 and iStent inject G2 in glaucoma service

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Glaucoma II

Venue: Poster Village: Pod 3

First Author: : S.Pipis UK

Co Author(s): :    G. Panos   A. Vergados                    

Abstract Details


A retrospective and comparative study in a real-world Glaucoma service of a 3 months follow up, where the effectiveness and safety of combined phaco surgery with implantation of trabecular micro-bypass device (iStent G1 or iStent inject G2) were evaluated.


Eye Treatment Centre, Whipps Cross University Hospital, Barts Health NHS Trust, London.


17 patients with cataract and POAG with >1 anti-glaucoma medication were included in this study. The primary efficacy endpoint was the intraocular pressure (IOP) reduction and secondary outcome was the number of medication pre-operatively and post-operatively. Safety outcomes included best-corrected visual acuity (BCVA), complications or secondary surgeries. The two groups shared similar characteristics with the exception the medication burden which was higher in patients who received the istent inject device.


G1-group (n=11): Median IOP-mmHg reduced from a baseline 18 (8-22), to 11 (10-21) at 12 weeks.(p=0.003). No significant changes in number of medication/ patient were observed. Median BCVA-Logmar improved from 0.4 (0.1–0.54) at baseline to 0.16 (0-0.4) at 12 weeks (p=0.002).  G2-group (n=6): Median IOP-mmHg reduced from a baseline 19 (16-30), to 9 (8-16) at 12 weeks (p<0.0001). No significant changes in number of medication/ patient were observed. Median BCVA -Logmar improved from 0.46 (0.15–2.3) at baseline to 0.2 (0.04-2.3) at 12 weeks (p=0.3). The hypotensive effect of iStent inject-G2 was significantly greater compared to iStent-G1 (p=0.008).


Significant and safe IOP reduction was observed in both groups. iStent-G2 inject has a greater hypotensive effect compared with the istent-G1.

Financial Disclosure:


Back to previous